Labcorp Reports Strong Q3 2026 Results and Raises Full-Year Guidance

Labcorp announced strong third-quarter 2026 financial results, highlighted by a 6.9% increase in revenue and a 14.5% rise in adjusted EPS compared to the prior year. Citing this performance, the company raised its full-year 2026 guidance for both revenue growth and adjusted EPS. Labcorp also advanced its M&A strategy, announcing or closing four transactions to expand its capabilities.

Key Details

• Q3 2026 Financial Performance: Revenue reached $3.81 billion (vs. $3.56 billion in Q3 2025), with Adjusted EPS of $4.78 (vs. $4.18 in Q3 2025).
• Raised 2026 Guidance: The company increased its full-year revenue growth forecast to a range of 5.9% to 6.7% and its Adjusted EPS guidance to a range of $18.30 to $18.70.
• Strategic Acquisitions: Labcorp closed the acquisition of MLM Medical Labs and announced agreements to acquire select assets from BioReference Health, Myriad Genetics' Prenatal Health business, and Millennium Health.